Advisor Group Holdings, Inc. Adaptimmune Therapeutics PLC Transaction History
Advisor Group Holdings, Inc.
- $42.1 Billion
- Q1 2025
A detailed history of Advisor Group Holdings, Inc. transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 65,058 shares of ADAP stock, worth $18,216. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65,058
Previous 15,258
326.39%
Holding current value
$18,216
Previous $8,000
62.5%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ADAP
# of Institutions
74Shares Held
114MCall Options Held
77.5KPut Options Held
14.2K-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$7.67 Million0.43% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR23.8MShares$6.65 Million0.16% of portfolio
-
Two Seas Capital LP Rye, NY20.5MShares$5.75 Million0.15% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$4.78 Million0.32% of portfolio
-
Mpm Asset Management LLC Cambridge, MA5.34MShares$1.49 Million1.54% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $45.7M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...